Leading Innovation and Delivering 21st Century Medicines
NEWS
Mr. Theo Godfrey joins SMDG's advisory board
SMDG team welcomes Mr. Theo Godfrey. Mr. Godfrey is a corporate and venture capital lawyer and a Partner in the London office of CMS Cameron McKenna Nabarro Olswang LLP. Much of his practice is focussed on transactions in the life sciences sector. He is an advocate for research and funding for rare paediatric diseases.
September 2024
Dr. Christy Hunter, well known chemist joins SMDG's management
SMDG team welcomes Dr. Christy Hunter as the Director of Chemistry. Dr Hunter has over 25 years of experience in Drug Delivery and Nanomedicine. "We are excited to welcome Dr. Christy Hunter, an accomplished and well-known chemist who has an impressive track record of scientific work over the last 25 years". Dr. Farhangrazi, CEO of SMDG.
August 2024
SMDG is a finalist in the Pharma Industry Award
SMDG is a finalist in two categories at the Pharma Industry Award UK 2024. SMDG is a finalist in the category, Research and Development Achievement Award: S. M. Discovery - Pioneering Therapeutic Platforms, NanoLigand Carriers, and Dr. Shadi Farhangrazi, CEO, has been selected as one of the finalists for the Women in Pharma Award.
August 2024
Dr Moein Moghimi appointed Editor in Chief
Professor Moein Moghimi, our Co-Founder and inventor of our therapeutic platforms has been appointed the Editor in Chief of the prestigious journal of "Drug Delivery". A Taylor and Francis Journal, Drug Delivery publishes open access peer-reviewed research on the development and application principles of drug delivery and targeting at molecular, cellular, and higher levels. Drug Delivery aims to serve both the academic and industrial communities and publishes papers on the following topics: All drug delivery systems, including oral, pulmonary, nasal, parenteral and transdermal delivery, All modes of drug entry, such as controlled release systems; Microcapsules, liposomes, vesicles, and macromolecular conjugates, Antibody targeting, Protein/peptide delivery, DNA, oligonucleotide and siRNA delivery.
April 2024
SMDG selected for Femtech and Women's Health Programme
SMDG has been selected to participate in the Discovery Park, Spark Femtech and Women's Health cohort programme. This is the first of its kind programme in the UK focusing on companies developing therapies for women's health. This is in recognition of our innovative and pioneering work on neurological diseases and women's health.
April 2024
SMDG announces appointment of industry leader Dr Zsuzsanna Devecseri to the Board of Directors
SMDG has appointed Dr Zsuzsanna Devecseri, M.D., MBA, to its Board of Directors (Board). Dr. Devecseri is a highly successful biopharmaceutical business executive who brings extensive leadership experience to SMDG as it progresses towards an important critical period of growth. Zsuzsanna Devecseri, MD, MBA, is the Global Head, Medical Affairs, Oncology, Novartis,
March 2024
Dr Farhangrazi invited for a Fireside Chat
Dr. Shadi Farhangrazi, our CEO, has been invited to join a fireside chat with Dr. Angela Cacace and Dr. Katie Digiananitonio from Arvinas, a clinical-stage biotechnology company leading the way in the development of targeted protein degradation therapeutics, based in New Haven, Connecticut, USA. The virtual conversation will be held on March 8th in commemoration of International Women's Day and will be attended by hundreds of Arvinas employees. The discussion will focus on Dr. Farhangrazi's journey as a scientist and woman.
March 2024